Skip to content

Efficacy of Ayurvedic Management on Timira with special reference to Simple Myopia

Efficacy of Katakaphaladi Varti Anjana and Dashanga Haritaki Modaka orally in the management of Timira with special reference to Simple Myopia- A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052565
Enrollment
100
Registered
2023-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H521- Myopia

Interventions

None listed

Sponsors

All India Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients presenting with signs and symptoms of Timira (Simple Myopia), described as per Ayurvedic and modern science irrespective of gender, occupation and religion. 2. Having spherical equivalent refraction between -0.50 diopter and -6.00 diopter. (calculated by adding the sum of the sphere power with half of the cylinder power.) 3. Willing to comply with applying Anjana twice daily and follow the clinical trial visit schedule as per the study protocol.

Exclusion criteria

Exclusion criteria: 1. Patients having high myopia ( >6 Diopter) or pathological myopia ( >8 Diopter) with degenerative retinal changes. 2. Patients having any other ocular pathology, e.g., strabismus, amblyopia, cataract, corneal opacity, iridocyclitis, retinal disease etc. will be excluded. 3. History of any disease or syndrome that predisposes the subject to severe myopia (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity, DM type 1). 4. Patients with the history of refractive correction through orthokeratology & refractive surgeries, etc.

Design outcomes

Primary

MeasureTime frame
Change in visual acuity using LogMAR chart.Timepoint: baseline, 46th day

Secondary

MeasureTime frame
â?¢ Change in Spherical equivalent refraction â?¢ Comparative efficacy of both the groups on asthenopic symptoms. â?¢ Pharmacognostic & physico-chemical study of Katakaphaladi Varti Anjana â?¢ Assessment of Ocular toxicity of Katakaphaladi Varti Anjana. Timepoint: baseline, 46th day

Countries

India

Contacts

Public ContactShikha Sharma

All India Institute of Ayurveda

eyenimi@gmail.com8368105917

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026